Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Up 17.3% – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) was up 17.3% during mid-day trading on Tuesday. The stock traded as high as $19.69 and last traded at $19.7390. 409,958 shares were traded during trading, an increase of 64% from the average daily volume of 249,784 shares. The stock had previously closed at $16.83.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. JonesTrading assumed coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price for the company. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price target for the company. TD Cowen started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating for the company. Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They set a “buy” rating and a $56.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics currently has a consensus rating of “Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Trading Up 14.4%

The firm’s 50 day simple moving average is $29.91. The firm has a market cap of $497.50 million, a P/E ratio of -0.14 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the last quarter. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics in the second quarter worth $3,610,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.